Mucosal immune system macrophages

The mucosal immune system is a specialized branch of the immune system that protects the body's internal surfaces, such as the gastrointestinal and respiratory tracts, with macrophages serving as central regulators of tissue homeostasis (Bain & Mowat, 2014, Nature Reviews Immunology). These macrophages are uniquely adapted to their environment, performing non-inflammatory phagocytosis of commensal bacteria and apoptotic cells while remaining capable of initiating robust immune responses against pathogens (Smith et al., 2011, Journal of Immunology). In chronic inflammatory conditions like Inflammatory Bowel Disease (IBD), the balance is disrupted as an influx of monocyte-derived macrophages produces excessive pro-inflammatory cytokines, including TNF-alpha, IL-12, and IL-23 (Neurath, 2014, Nature Reviews Immunology). Therapeutic strategies targeting this system often involve monoclonal antibodies that neutralize these cytokines or block the trafficking of leukocytes to the mucosa, such as Infliximab or Vedolizumab (Sandborn et al., 2013, NEJM). While these treatments are effective in reducing inflammation, they carry risks of systemic immunosuppression and increased susceptibility to opportunistic infections (Rutgeerts et al., 2005, Gastroenterology). Consequently, current research focuses on identifying more specific pathways within mucosal macrophages to restore immune tolerance without compromising overall host defense.

Other names

Intestinal macrophagesGut-associated lymphoid tissue (GALT) macrophagesMucosa-associated lymphoid tissue (MALT) macrophagesLamina propria macrophagesIntestinal mononuclear phagocytes

Modulation of the mucosal inflammatory environment through the neutralization of pro-inflammatory cytokines (e.g., TNF-alpha, IL-12, IL-23), blockade of leukocyte trafficking to the gut (e.g., alpha-4-beta-7 integrin inhibition), or suppression of intracellular signaling pathways (e.g., JAK-STAT inhibition) within immune cells.